

RECEIVED  
CENTRAL FAX CENTER

JUL 13 2006



Vertex Pharmaceuticals Incorporated  
130 Waverly Street • Cambridge, MA 02139-4242  
Tel. 617.444.6100 • Fax 617.444.6483  
<http://www.vpharm.com>

---

## FAX TRANSMISSION

To	United States Patent and Trademark Office
Examiner	Kahsay Habte
Group Art Unit	1624
From	Karen E. Brown
Date	July 13, 2006
Application No.	10/700,936
Attorney Docket No.	VPI/02-123 US
	Amendment and Reply to Office Action
Total Pages	33

Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-6168 immediately.

RECEIVED  
CENTRAL FAX CENTER

002/033

JUL 13 2006


Attorney Docket No.: VPI/02-123 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/700,936  
Confirmation No.: 5983  
Filing Date: November 4, 2003  
Examiner: Kahsay Habte  
Group Art Unit: 1624  
Applicants: Randy S. Bethiel et al.  
For: COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER  
PROTEIN KINASES

**Certificate of Facsimile Transmission Under 37 CFR 1.8**

I hereby certify that this correspondence and any documents referred to as attached hereto are being facsimile transmitted to: Mail Stop Amendment, Commissioner for Patents, the United States Patent and Trademark Office on July 13, 2006.



Signature

Lisa M. Romano

Typed or Printed Name

July 13, 2006  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Transmitted herewith: ☒ a Reply to Office Action; ☒ a Petition for Extension of Time; ☐ a substitute Specification; ☐ a Declaration; ☐ a Supplemental Declaration; ☐ a Power of Attorney; ☐ an Associate Power of Attorney; ☐ formal drawings; ☐ Notice of Appeal; ☐ Appeal Brief; ☐ \_\_\_\_\_; to be filed in the above-identified patent application.

07/14/2006 MBINAS 00000033 500725 10700936

01 FC:1253 1020.00 DA

Applicants:	Kahsay Bethiel et al.
Application No.:	10/700,936

FEE FOR ADDITIONAL CLAIMS

☒ A fee for additional claims is not required.

☐ A fee for additional claims is required.

The additional fee has been calculated as shown below:

CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEES
TOTAL CLAIMS	-	* =	X \$ 50	= \$ 0
INDEPENDENT CLAIMS	-	** =	X \$ 200	= \$ 0
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM		+	\$ 360	= \$
				TOTAL \$ 0
				* If less than 20, insert 20.
				** If less than 3, insert 3.

☐ A check in the amount of \$\_\_ in payment of the filing fee is transmitted herewith.

☐ Please charge \$\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

☒ The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Applicants:	Kahsay Bethiel et al.
Application No.:	10/700,936


EXTENSION FEE

- ☒ The following extension is applicable to the Response filed herewith; ☐ \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); ☐ \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); ☒ \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); ☐ \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); ☐ \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- ☐ A check in the amount of ☐ \$120.00; ☐ \$450.00; ☐ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 in payment of the extension fee is transmitted herewith.
- ☒ Please charge the extension fee in the amount of ☐ \$120.00; ☐ \$450.00; ☒ \$1,020.00; ☐ \$1,590.00; ☐ \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- ☒ The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

MISCELLANEOUS FEES

- ☐ Please charge \$\_\_\_\_\_ to Deposit Account No. 50-0725 in payment of the fee for \_\_\_\_\_ (37 C.F.R. § \_\_\_\_\_).
- ☒ The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § \_\_\_\_\_, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

  
Karen E. Brown, Reg. No. 43,866  
Attorney/Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483  
Customer No. 27916